Reich Kristian 4
4 · MoonLake Immunotherapeutics · Filed Jun 17, 2026
Research Summary
AI-generated summary of this filing
MoonLake (MLTX) CSO Kristian Reich Sells 150,000 Shares
What Happened
Kristian Reich, Chief Scientific Officer of MoonLake Immunotherapeutics (MLTX), sold a total of 150,000 ordinary shares in three open‑market transactions between June 15 and June 17, 2026, generating approximately $2.85 million in proceeds (50,000 shares on 6/15 for $944,500; 50,000 on 6/16 for $935,000; 50,000 on 6/17 for $971,500). Each line item was reported as a sale (S).
Key Details
- Transaction dates and weighted‑average prices:
- 2026-06-15: 50,000 shares @ $18.89 (weighted average; individual prices ranged $18.66–$19.12). (F2)
- 2026-06-16: 50,000 shares @ $18.70 (weighted average; individual prices ranged $18.235–$19.33). (F4)
- 2026-06-17: 50,000 shares @ $19.43 (weighted average; individual prices ranged $18.915–$19.97). (F5)
- Total proceeds: $2,851,000.
- Plan/authorization: Transactions were executed pursuant to a Rule 10b5‑1 trading plan adopted March 10, 2026. (F1)
- Beneficial ownership note: Some shares are held by JeruCON Beratungsgesellschaft mbH, of which Dr. Reich may be deemed an indirect beneficial owner for Section 16 purposes. (F3)
- Shares owned after the transactions: not specified in the provided filing excerpt.
- Filing timing: Report filed June 17, 2026 (appears timely relative to reported trades).
Context
These were open‑market sales under a pre‑arranged 10b5‑1 plan, which typically indicates planned dispositions rather than ad‑hoc trading. The filing is factual and does not state reasons for the sales; retail investors often view purchases as stronger signals of insider conviction than routine sales.
Insider Transaction Report
- Sale
Class A ordinary shares, par value $0.0001 per share
[F1][F2][F3]2026-06-15$18.89/sh−50,000$944,500→ 2,924,551 total(indirect: See footnote.) - Sale
Class A ordinary shares, par value $0.0001 per share
[F1][F4][F3]2026-06-16$18.70/sh−50,000$935,000→ 2,874,551 total(indirect: See footnote.) - Sale
Class A ordinary shares, par value $0.0001 per share
[F1][F5][F3]2026-06-17$19.43/sh−50,000$971,500→ 2,824,551 total(indirect: See footnote.)
- 35,389
Class A ordinary shares, par value $0.0001 per share
Footnotes (5)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026.
- [F2]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $18.66 to $19.12. Upon request by the staff of the U.S. Securities and Exchange Commission (the "Commission"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F3]Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.
- [F4]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $18.235 to $19.33. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F5]The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $18.915 to $19.97. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.